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Background: Staphylococcus aureus causes an array of diseases in 
both humans and livestock. Pathogenesis is mediated by a plethora of 
proteins secreted by S. aureus, many of which remain incompletely 
characterised. For example, S. aureus abundantly secretes two 
isoforms of the enzyme lipase into the extracellular milieu, where they 
scavenge upon polymeric triglycerides. It has previously been 
suggested that lipases may interfere with the function of innate 
immune cells, such as macrophages and neutrophils, but the impact 
of lipases on phagocytic killing mechanisms remains unknown. 
Methods: We employed the epidemic S. aureus clone USA300 strain 
LAC and its lipase deficient isogenic mutant, along with recombinant 
lipase proteins, in in vitro experimental infection assays. To determine 
if lipases can inhibit innate immune killing mechanisms, the 
bactericidal activity of whole blood, human neutrophils, and 
macrophages was analysed. In addition, gentamycin protection assays 
were carried out to examine the influence of lipases on S. aureus 
innate immune cell escape. 
Results: There were no differences in the survival of S. aureus USA300 
LAC wild type and its lipase-deficient isogenic mutant after incubation 
with human whole blood or neutrophils. Furthermore, there was no 
detectable lipase-dependent effect on phagocytosis, intracellular 
survival, or escape from both human primary and immortalised cell 
line macrophages, even upon supplementation with exogenous 
recombinant lipases. 
Conclusions: S. aureus lipases do not inhibit bacterial killing 
mechanisms of human macrophages, neutrophils, or whole blood. 
These findings broaden our understanding of the interaction of S. 
aureus with the innate immune system.
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Introduction
The Gram-positive bacterium Staphylococcus aureus is the 
cause of an array of nosocomial and community-acquired infec-
tions. To be a successful pathogen, S. aureus must evade killing 
by the innate immune system which it does via a large number 
of secreted factors. Within the Staphylococcus genus, a lipase-
encoding gene (lip1) is present in at least 12 species, and a sec-
ond lipase gene is present in S. aureus (lip2) and S. epidermidis 
(gehD)1,2. S. aureus lipases are glycerol-ester hydrolases that 
cleave triglyceride lipids, resulting in the release of glycerol 
derivatives and free fatty acids1. Lipase 1 has an affinity for 
short-chain fatty acids, whereas lipase 2 has no bias towards 
chain length1. Transcription of lipase genes is regulated by the 
accessory gene regulator (agr) two component system, leading 
to the expression of a pre-pro-lipase precursor that is secreted 
into the extracellular milieu1,3. The catalytic activity of lipases is 
regulated through downstream processing by the secreted zinc 
metalloprotease, Aur, which proteolytically cleaves the pre-
pro precursor enzyme resulting in the mature, active form of 
the enzyme4. The activity of the mature lipase is governed by a 
catalytic triad, which cleaves glycerol-ester bonds through a 
serine hydrolase mechanism1,2. Lipases have been reported to 
account for approximately 20% of the total S. aureus secre-
tome, but our understanding of the role of lipases in host- 
pathogen interactions is limited5. It has been shown that 80% of 
clinical isolates from both systemic and localised S. aureus infec-
tions exhibit lipolytic activity, and patients typically test posi-
tive for anti-lipase IgG in serum6,7. Lipases have further been 
attributed to the formation of biofilm, which subsequently 
confers resistance to toxic polyamines thus promoting bacterial 
persistence3,8,9. Previous studies have further demonstrated that 
lipases can produce free-fatty acids from host lipid metabolites, 
such as low-density lipoproteins, which subsequently are incor-
porated into the lipid moieties of S. aureus10. The incorporation 
of lipoprotein particles has been shown to render the bacterium 
resistant to the antimicrobial drug triclosan, which is commonly 
used in the treatment of S. aureus infection10.
In a previous study, human granulocytes were treated with 
S. aureus lipases resulting in the loss of microvilli, projec-
tions, and pseudopodia on their surface suggesting a potential 
impact on phagocytosis or neutrophil extracellular trap (NET) 
formation11,12. More recently, it was demonstrated that lipase 
2 interferes with macrophage signalling, which subsequently 
diminishes the downstream pro-inflammatory response13. Specifi-
cally, lipase 2 inactivates S. aureus secreted lipoproteins, which 
are a major pattern-associated molecular pattern recognised by 
Toll-like receptor 2 (TLR2) in response to S. aureus infection13.
Macrophages are equipped with an array of pathogen recogni-
tion receptors and, alongside a role in modulation of cellular 
signalling, are professional phagocytes that aid in the clearance 
S. aureus14,15. However, studies have shown that once entrapped 
within the macrophage phagolysosome, S. aureus can subvert 
killing mechanisms and persist for several days16,17. The sub-
sequent death of the macrophage through membrane blebbing 
and caspase-3 activation results in the release of viable 
bacteria, promoting intra-host dissemination in a Trojan horse-like 
system14,17,18.
Here, we tested the hypothesis that lipases can interfere with 
the antibacterial activity of whole blood, neutrophils and macro-
phages. We report that, despite their abundant secretion, lipases 
have no effect on killing, phagocytosis, intracellular survival 
or escape of S. aureus USA300 LAC.
Methods
Bacterial growth conditions
40% (v/v) glycerol stocks of both a wild type (S. aureus 
USA300 WT) and an isogenic mutant (S. aureus USA300 
Δlip1/Δlip2) of the CC8 epidemic clone S. aureus USA300 LAC 
generated in a previous study19 were stored at -80°C. When 
required, stocks were sub-cultured onto tryptone soy agar (TSA, 
Oxoid CM131B) or cultured into tryptone soy broth (TSB, 
Oxoid CM129B) overnight at 37°C with agitation (200 rpm). 
The culture was diluted 1 in 100 in TSB and incubated, until 
exponential phase (OD
600
=0.6–0.8), as measured using an 
Amersham Biosciences Ultrospec 2100 pro spectrophotometer. 
For infection protocols, bacteria were washed in cell culture 
media and suspended at the required OD
600
.
Purification of recombinant lipase1 (rLip1) and 2 (rLip2)
Expression plasmid constructs pET156::lip1 or pET156::lip219 
were transformed into ClearColi® BL21 (DE3) electrocompe-
tent cells (Lucigen, 60810-1) by electroporation, according to the 
manufacturer’s instructions. Cells were grown in LB Miller broth 
(Sigma, L3522-250G) to an OD
600
 of 0.6 and protein expres-
sion was induced with 1 mM isopropyl β-D-1-thiogalactopyra-
noside (IPTG, Formedium Ltd, IPTG025) for 4 h at 37°C, with 
agitation (200 rpm), before centrifugation and storage at -20°C.
Hexa-histidine tagged proteins were purified by immobilised 
metal affinity chromatography as described previously19. West-
ern blot analysis confirmed the presence of hexa-histidine tagged 
proteins at 76 kDa (1 in 10,000 monoclonal anti-poly His, 
α-diagnostics HISP12-HRP, in 8% (w/v) skimmed milk (Sigma, 
70166-500G) in sterile phosphate buffered saline (PBS)). Pri-
mary antibody binding was detected using enhanced luminol- 
based chemiluminescent (ECL) western blotting substrate 
(GE Healthcare, RPN2232). For lipopolysaccharide (LPS) 
removal, 1 ml of Pierce high capacity endotoxin removal resin 
(Thermo Fisher Scientific, 88271) was used according to the 
manufacturer’s instructions and proteins were quantified using 
a bicinchoninic acid (BCA) assay (Merck millipore, 71285-3). 
To analyse recombinant protein lipolysis, a turbiometric assay 
was used following the methodology outlined previously20. 
For each of the following experiments, 200 nM of recombinant 
lipase 1 (rLip1) or 2 (rLip2) was used, according to previous 
estimates of lipase secretion levels by S. aureus21.
Ethics statement
Human blood was obtained from healthy volunteers in syringes 
treated with anticoagulant citrate dextrose. Ethical approval 
for the collection of blood from anonymous donors was granted 
by the University of Edinburgh Research Ethics Committee. 
This study was reviewed by the University Of Edinburgh 
College Of Medicine Ethics Committee (2009/01) and subse-
quently renewed by the Lothian Research Ethics Committee 
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(11/AL/0168). Written informed consent was received from all 
volunteers participating in the study.
Bacterial killing by neutrophils
Neutrophils were purified from human blood using a ficoll gra-
dient. Briefly, 10 ml of 1.077 g/mol ficoll paque plus (Fisher, 
11778538) was gently layered onto 12 ml of 1.119 g/mol 
Histopaque plus (Sigma, 11191). Fresh human blood was diluted 
at a 1:1 ratio in Ca2+ and Mg2+ free PBS (Lonza, BE17-515F), 
then slowly pipetted onto the ficoll gradient prior to centrifu-
gation for 20 min at 400 × g (without a brake). The neutrophil 
layer was collected, cells were centrifuged and erythrocytes 
lysed by osmotic shock. Cells were suspended in RPMI-1640 
(Sigma, R5886), 0.05% (v/v) human serum albumin (Sigma, 
A9080-10ML) and 1% (v/v) GlutaMAX (Gibco, 35050-061) 
prior to use. 50 µl of 1.5 × 105 colony forming units (CFU) of 
S. aureus USA300 WT or S. aureus USA300 Δlip1/ Δlip2 bacterial 
cells were opsonised in 50 µl of 10% autologous human plasma 
for 15 min in a 96 well Cellstar U bottomed plate (Greiner Bio-
One Inc, 650101) (37°C). Subsequently, 1.5 × 10 4 neutrophils 
(MOI=10) were incubated with the bacteria in the presence 
or absence of 200 nM rLip1 or rLip2. The plate was shaken 
at 600 rpm for 30 min at 37°C followed by cell lysis in 0.1% 
Triton X-100 (Sigma, P6416-100ML) and plated onto TSA 
using a modified Miles-Misra technique22, whereby 10 µl of each 
10-fold bacterial dilution was plated, followed by incubation 
overnight at 37°C and counting of colonies.
Bacterial killing by whole blood
75 µl of whole blood was infected with 25 µl of 1. 5 × 105 CFU 
of S. aureus USA300 WT and S. aureus USA300 Δlip1/Δlip2 
in the presence or absence of 200 nM rLip1, rLip2 or both in a 
96 well Cellstar U bottomed plate for 1, 2 and 4 h at 37°C, 
with shaking at 200 rpm. Blood was lysed in 0.1% (v/v) 
TritonX-100 (Sigma), viable bacteria counts were determined 
with 10 µl of ten-fold bacterial dilutions in PBS onto TSA using 
a modified Miles-Misra technique22 and incubated overnight 
at 37°C.
Isolation of CD14+ monocytes
Monocytes were isolated from human whole blood follow-
ing centrifugation at 1200 x g (no break) for 20 min. Buffy 
coats were combined and diluted with PBS and subsequently 
slowly pipetted over 15 ml of 1.199 g/mol ficoll paque plus 
(Sigma). A gradient was generated by centrifugation for 
45 min at 200 x g (no break), in which the mononuclear cell 
layer was subsequently removed. Ficoll was removed by 
centrifugation for 10 min with 300 x g, and resuspension in 
PBS. CD14+ monocytes were collected using a MAC-LS 
column as per the manufacturer’s instructions (Miltenyi Biotec, 
130-042-401).
Macrophage differentiation
For THP1 differentiation into macrophages, 5 × 105 THP1 
cells were seeded in a 96-well Nunc flat bottomed plate in 
RPMI-1640 (Sigma), 10% (v/v) heat-inactivated foetal bovine 
serum (Gibco, 10270-106) and 1% (v/v) GlutaMAX (Gibco) 
in the presence of 200 nM phorbol 12-myristate 13-acetate 
(PMA, VWR P1585-1MG) for 3 d, before being left to rest 
for 1 d in media without PMA. For blood monocyte-derived 
macrophages, 5 × 105 of purified human blood CD14+ cells were 
incubated for 5 d in 1:100 dilution of 104 U/ml recombinant 
human colony-stimulating factor-1 (hCSF-1, provided by Prof. 
D. Hume) in media. On the 5th day, cells were topped up with 
25% complete medium containing 3 × the target concentration of 
hCSF-1 and cells were used at day 7.
Gentamycin-protection assay
THP1 macrophages and blood-monocyte derived macro-
phages were infected at an MOI of 1 with bacteria suspended in 
fresh media (RPMI-1640 (Sigma), 10% (v/v) heat-inactivated 
foetal bovine serum (Gibco) and 1% (v/v) GlutaMAX 
(Gibco). Cells were centrifuged at 400 x g for 5 min and incu-
bated for 1 h at 37°C, 5% CO
2
. For analysing internalised bac-
teria (phagocytosis), cells were subsequently incubated with 
100 µg/ml gentamycin (Sigma, G1397-10ML) in cRPMI for 
30 min. To analyse intracellular survival, cells were subse-
quently left in 20 µg/ml gentamycin in media and were incu-
bated for a further 24 h at 37°C, 5% CO
2
. Finally, to analyse the 
escape of intracellular bacteria, cells were incubated for 24 h 
in antibiotic-free media at 37°C, 5% CO
2
. At each time point, 
corresponding to the degree of phagocytosis, bacterial intracel-
lular survival, and bacterial escape from the macrophage, cells 
were lysed in 0.1% Triton X-100 in PBS for 5 min at room 
temperature, and viable cell counting by plating onto TSA as 
described above.
Statistical methods
Statistical analysis was performed with GraphPad Prism 8 
software (GraphPad, USA).
Results
Lipases do not inhibit S. aureus survival in human whole 
blood
Peripheral whole blood contains an array of innate immune 
components involved in the direct killing of S. aureus23–27. To 
evaluate if lipases can promote S. aureus survival in blood, 
human whole blood was incubated with S. aureus USA300 LAC 
(S. aureus USA300 WT) or its isogenic mutant deficient in both 
lipase 1 and lipase 2 production (S. aureus USA300 Δlip1/Δlip2) 
for 1, 2, and 4 h at 37°C. Concurrently, S. aureus USA300 
Δlip1/Δlip2 was also incubated with 200 nM of function-
ally active rLip1 and rLip2 (Extended Figure 128). There was 
a 10-fold reduction in the number of recoverable bacteria in the 
first hour post-infection, followed by a stabilisation of the number 
of viable bacteria recovered up to 4 h, but there was no differ-
ence between the S. aureus USA300 WT and the lipase-deficient 
mutant or strains supplemented with recombinant lipase 
(Figure 128). Overall, these data indicate that lipases do not 
inhibit killing of S. aureus USA300 LAC in human whole 
blood.
S. aureus lipases do not inhibit neutrophil bactericidal 
activity
It was previously demonstrated that purified S. aureus lipases 
alter the phenotype of granulocytes, suggesting a possible impact 
on their function11,12. To establish if lipases can inhibit neu-
trophil killing of S. aureus, human neutrophils were isolated from 
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fresh whole blood and incubated with opsonised S. aureus 
USA300 WT or S. aureus USA300 Δlip1/Δlip2 for 30 min. As 
with whole blood, there was a 10-fold reduction in the number 
of viable bacteria after incubation with neutrophils, but viabil-
ity between the S. aureus USA300 WT and the lipases-deficient 
strain did not differ (Figure 228). In addition, neutrophils were 
incubated with S. aureus USA300 Δlip1/Δlip2 in the presence 
of exogenous recombinant lipases and there were no differ-
ences in the number of recovered viable bacteria between the 
tested conditions (Figure 228). Taken together, these data indi-
cate that lipases do not inhibit neutrophil-mediated killing of 
S. aureus USA300 LAC.
Lipases do not influence phagocytosis, intracellular 
survival or escape of S. aureus from macrophages
Recently, it was demonstrated that lipolysis of S. aureus lipopro-
teins by lipase 2 facilitated the survival of S. aureus through the 
manipulation of macrophage cellular signalling13. In addition, 
S. aureus can interfere with macrophage phagolysosomal kill-
ing, enabling intracellular persistence16. To examine the capacity 
for S. aureus lipases to influence phagocytosis, intracellular sur-
vival, and escape from macrophages, primary human monocyte-
derived macrophages were incubated with S. aureus USA300 WT 
or S. aureus USA300 Δlip1/Δlip2 in the presence or absence of 
rLip1 or rLip2 (Figure 3a28). Considerable variation in the number 
of recovered bacteria was observed between technical repli-
cates due to donor variability, but no significant lipase-dependent 
differences were observed (Figure 3b28). To further explore the 
effect of lipases on macrophage function, an immortalised cell 
line derived from human peripheral blood monocytes (THP1) 
cells was employed29. PMA induces THP1 monocyte differen-
tiation into adherent macrophages which represent a model of 
human monocyte-derived macrophages30. S. aureus USA300 LAC 
infection of THP1 macrophages exhibited less variation between 
Figure 1. Lipases do not promote survival of S. aureus in human whole blood. Human whole blood was collected from healthy donors 
(each donor represented by a different symbol) and incubated with S. aureus USA300 WT or S. aureus USA300 Δlip1/Δlip2, alongside S. aureus 
USA300 Δlip1/Δlip2 supplemented with 200 nM rLip1 and/or rLip2 for 0, 1, 2 and 4 h, at 37°C (with agitation). Each symbol represents the 
average of technical triplicates. Two-way ANOVA with Tukey’s multiple comparisons. Bars show mean + SD, n=4.
Figure 2. Lipases do not inhibit human neutrophil bactericidal activity. Human neutrophils were isolated from healthy donors (each 
donor represented by a different symbol) and incubated with plasma opsonised S. aureus USA300 WT or S. aureus USA300 Δlip1/Δlip2 at an 
MOI of 10, in the presence or absence of 200 nM rLip1 and/or rLip2 for 30 min at 37°C (with vigorous agitation). Each symbol represents the 
mean of 5 technical replicates for an individual donor. One-way ANOVA with Tukey’s multiple comparisons. Bars show mean + SD, n=3.
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replicates when compared to primary cultures but no lipase-
dependent differences in the number of bacteria recovered was 
observed (Figure 3c28). Together, these data indicate that lipases 
do not affect phagocytosis, survival or escape of S. aureus from 
human macrophages.
Discussion
The importance of neutrophils in the initial response to 
S. aureus infection is well established24,31. Previously, Rollof 
et al., demonstrated, using scanning electron microscopy, 
that supernatant-purified S. aureus lipases altered granulocyte 
Figure 3. Lipases do not affect bacterial survival in human blood monocyte or THP1 derived macrophages. (a) Schematic of 
the assay used to analyse the phagocytosis, intracellular proliferation and escape of S. aureus from within macrophages. (b) Primary 
macrophages were differentiated from human blood monocytes isolated from 3 different healthy donors (represented by different symbols) 
and were incubated with S. aureus USA300 WT or S. aureus USA300 Δlip1/Δlip2, alongside S. aureus USA300 Δlip1/Δlip2 supplemented with 
200 nM rLip1 and/or rLip2 as per the schematic in Fig 4a, followed by plating and viable counting. (c) THP1 macrophages were incubated 
with S. aureus USA300 WT or S. aureus USA300 Δlip1/Δlip2, alongside S. aureus USA300 Δlip1/Δlip2 supplemented with 200 nM rLip1 and/
or rLip2 following the schematic in Fig 4a. CFU analysis of phagocytosis, 24 h intracellular survival and 24 h escape was quantified for 
3 technical replicates. Paired data was analysed using a two-way ANOVA, Tukey’s multiple comparisons. Bars show mean + SD, n=3.
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morphology by denuding surface projections11. As neutrophil 
phagocytosis is reliant on pseudopod extensions for ingesting 
bacteria, it was hypothesised that this phenotype could inhibit 
bactericidal activity24. Furthermore, the release of extracellular 
DNA into the environment, through NETosis, could be impacted 
by lipase-mediated changes to the cellular membrane which 
could influence bacterial killing.
Here, we demonstrate that lipases do not inhibit direct killing 
of S. aureus mediated by human neutrophils, macrophages 
or whole blood in vitro. The findings are consistent with the 
findings of Nguyen et al., who did not observe any differences 
in bacterial burden in the heart and liver in an in vivo 
murine sepsis model 24 h after infection with S. aureus 
USA300 WT LAC or an isogenic lipase-deficient mutant3. 
These data suggest that lipases do not interfere with the initial 
clearance of S. aureus from the blood.
A recent study by Chen et al., reported that lipases have no 
direct effect on initial bacterial clearance in the early 
stages of infection. However they demonstrated that after 
48 h, there was an indirect effect of lipase 2 resulting in 
reduced pro-inflammatory cytokine release by macrophages13. 
The authors found that S. aureus lipase 2 mediates cleavage 
of S. aureus lipoproteins, which are well characterised TLR2 
ligands, resulting in increased bacterial burden by thwarting 
macrophage responses. 
Previously it has been shown that S. aureus virulence factors 
regulated by the agr quorum-sensing system are required for 
survival and escape of S. aureus from macrophages, includ-
ing the zinc metalloprotease Aur which is responsible for the 
downstream activation of the catalytically active lipases16,32,33. 
Here, we report that the agr-regulated lipases do not influence the 
survival of S. aureus in human monocyte-derived macrophages, 
although considerable donor specific variation was observed 
with primary cells. Data obtained using the THP1 macrophage 
cell line further support the finding that S. aureus lipases do not 
affect phagocytosis, intracellular survival or escape of S. aureus 
from human macrophages. The lack of an observable effect 
of lipases may reflect the fact that bacterial capture by macro-
phages is dependent on dynamic actin-rich protrusions, with 
negligible involvement of triglyceride lipids in the process34.
Conclusion
Overall, we report that S. aureus lipases do not directly impact 
on the killing mechanisms of neutrophils and macrophages. 
These data add to our understanding of S. aureus interactions 
with the innate immune system and the role of lipases in the 
pathogenesis of S. aureus disease.
Data availability
Underlying data
Edinburgh Datashare: Staphylococcus aureus secreted lipases 
do not inhibit innate immune killing mechanisms: Extended 
Figure 1. https://doi.org/10.7488/ds/288128 
This project contains the following underlying data:
-     Validation of rLip1 and rLip2.xlsx (ClarioSTAR (BMG 
Labtech) readouts of both rLip1 and rLip2, alongside 
400 nM BSA. Absorbance was measured at OD
495 
every 
5 min for 20 h. Each experiment contained three 
technical repeats, n=3)
-     Recombinant lipases Western blot, raw-unedited image.
jpg (Raw gel image for Western presented in Extended 
Figure 1)
Extended data
Edinburgh Datashare: Staphylococcus aureus secreted lipases 
do not inhibit innate immune killing mechanisms: Extended 
Figure 1. https://doi.org/10.7488/ds/288128
-     Extended Figure 1.docx
Extended Figure 1: Functional characterisation of puri-
fied recombinant S. aureus lipase 1 and 2. (a) Purification 
of recombinant lipase 1 and 2 was analysed using west-
ern blot, in which bands present at 76 kDa indicated the cor-
rect protein elution (detected by hexa-his tag, α-diagnostics 
HISP12-HRP). Page-Ruler ladder (furthest left well) shows 
the visible protein marker at 75 kDa. Measurement of lipolytic 
activity of recombinant protein 1 (rLip1) (b) and 2 (rLip2) (c). 
It was observed that both lipase 1 and 2 were functionally active 
enzymes which were able to cleave Tween-20 over a broad 
scope of concentrations. Indeed, it was also observed that lipase 
2 was much more kinetically active in comparison to lipase 
1, which could be attributed to its broader substrate range. 
Two-way ANOVA, Dunnets Multiple Comparisons against 
the BSA negative control, α=0.05, **** p<0.001. Each point 
shows mean + SD (Data represent a representative experiment, 
from three independent experiments).
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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